Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.35 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14023348 | 1.00 | HINT1 (0.40) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL5217045 | 1.00 | HINT1 (0.40) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL14023346 | 0.92 | HINT1 (0.42) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL14581405 | 0.91 | HINT1 (0.49) | HINT1CYP1A2STING1 | |
| SCHEMBL5435997 | 0.90 | NT5E (0.41) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL9202661 | 0.90 | NT5E (0.41) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL14023347 | 0.90 | NT5E (0.41) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL5216986 | 0.90 | NT5E (0.41) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL5216981 | 0.90 | NT5E (0.41) | HINT1CYP1A2LMNASTING1PNP | |
| SCHEMBL5425043 | 0.90 | NT5E (0.41) | HINT1CYP1A2LMNASTING1PNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265890-B1 | STEREOSELECTIVE SYNTHESIS OF NUCLEOSIDE ANALOGUES | SHIRE BIOCHEM INC (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-6743910-B2 | VIRICIDES, ANTICANCER AGENTS | BIOCHEM PHARMA, INC. (CA) | 2004-06-01 | — | — | US | disclosed |
| US-20030187262-A1 | Stereoselective synthesis of nucleoside analogues | BIOCHEM PHARMA INC. (CA) | 2003-10-02 | — | — | US | disclosed |
| US-6541625-B2 | Stereoselectively hydrolyzing an anomeric mixture of 2-benzoyloxydioxolanecarboxylate with an enzyme; separating product; replacing carboxylate by reaction with a purine or pyrimidinyl derivative | BIOCHEM PHARMA, INC. (CA) | 2003-04-01 | — | — | US | disclosed |
| US-20020006635-A1 | Stereoselective synthesis of nucleoside analogues | BIOCHEM PHARMA, INC. (CA) | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187262-A1 | Stereoselective synthesis of nucleoside analogues | PNP, CTRC, CPN1 | HINT1 620/4885CYP1A2 2879/4885LMNA 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.